Since no information is available regarding the concurrent inhibition of anti-apoptotic proteins and mTOR-mediated pro-survival signaling under CRC tumor hypoxia, we investigated response to treatment with ABT-737 and AZD8055, in this report referred to as combo-Rx, in a panel of hypoxic CRC cell lines harboring various typical mutations. The gene discussed is MTOR; the disease is colorectal carcinoma.